Supplemental Figure 1 from Augmenting CAR T-cell Functions with LIGHT

(A) Transgene expression of the CAR constructs after retroviral transduction of human T cells by flow cytometry. CD19 CAR T cells were used as irrelevant CAR T cell control. (B-D) Healthy human donor-derived mesothelin-targeted CAR T cells were cocultured with tumor cells expressing GFP and firefly luciferase at different effector to tumor ratios. Bioluminescence was measured 72 hours later and plotted as a percentage of the signal detected with tumor cells alone (max bioluminescence signal). Associated expression of mesothelin with the corresponding mesothelin-positive cell lines are shown. JMN (left), SW620 (middle), and MDA-MB-231 (right). Plots represent 3 independent experiments. Data errors were analyzed with mean ± SEM. (E) HVEM expression in PDAC cell lines (CAPAN2, AsPC1, BxPC3, Panc1) (F) Flow cytometric analysis of overexpression constructs derived from Panc1 wildtype. Panc1 Mesothelin overexpression, Panc1 LTβR overexpression, and Panc1 Mesothelin and LTβR Overexpression